Enveda Raises $150M Series D Funding to Reach Unicorn Status with the support of Premji Invest. The funds will enhance their clinical pipeline and accelerate development.
Amount Raised
$150 Million
Round Type
Series D
BoulderOtherBiotechnologyInvestors
Description
Enveda, a clinical-stage biotech company, has closed an oversubscribed $150 million Series D financing round. The funding will support the advancement of its clinical pipeline addressing major medical needs. The round was led by Premji Invest, with contributions from various investors. Additionally, Enveda has enrolled its first patient in a Phase 1b clinical trial for lead program ENV-294.
Quick answer
Enveda Therapeutics, Inc. raised $150 Million in a Series D round, dated September 4, 2025. Investors: Peakline Partners, Lingotto Investment Management, Lux Capital, IA Ventures, Henry Kravis, Baillie Gifford, Kinnevik and Fpv. Enveda Therapeutics, Inc. is based in Boulder, Colorado, United States.
- How much did Enveda Therapeutics, Inc. raise?
- Enveda Therapeutics, Inc. raised $150 Million in a Series D round on September 4, 2025.
- Who invested in Enveda Therapeutics, Inc?
- Peakline Partners, Lingotto Investment Management, Lux Capital, IA Ventures, Henry Kravis, Baillie Gifford, Kinnevik and Fpv are named as investors in this round.
- What does Enveda Therapeutics, Inc. do?
- Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery.
- Where is Enveda Therapeutics, Inc. based and how big is it?
- Enveda Therapeutics, Inc. is based in Boulder, Colorado, United States. Fundz records about 387 employees.
- Who are the decision-makers at Enveda Therapeutics, Inc?
- Fundz holds 5 contacts at Enveda Therapeutics, Inc., including the Associate Director Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Enveda Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Theriva Biologics raised $13M on October 17, 2025.
- Protego Biopharma raised $33M on October 17, 2025.
- AB Science raised $3.3M (Post-IPO Equity) on October 17, 2025.
- Andson Biotech raised $4.7M (Seed) on October 17, 2025.
- BridGene Biosciences raised $28M (Series B) on October 16, 2025.
- Codis raised an undisclosed amount (Funding Round) on October 16, 2025.
Who to call at Enveda Therapeutics, Inc., and when
A new round usually means Enveda Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Enveda Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Enveda Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Enveda Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Enveda Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Enveda Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.